Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
completion around

Description

Summary

This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation.

Official Title

A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination With Dabrafenib for the Treatment of Advanced Solid Tumors With MAPK Pathway Mutations

Details

Keywords

Solid Tumors, solid tumor, neoplasm, BRAF V600 mutation, MAPK pathway mutation, ERK1/2, JSI-1187, Dabrafenib, KRAS, NRAS, BRAF, melanoma, non-small cell lung cancer, anaplastic thyroid cancer, Neoplasms, JSI-1187 Plus Dabrafenib Expansion

Eligibility

Locations

  • University of California Helen Diller Family Comprehensive Cancer Center
    San Francisco California 94158 United States
  • Mayo Clinic Cancer Center
    Phoenix Arizona 85054 United States

Details

Status
currently not accepting new patients, but might later
Start Date
Completion Date
(estimated)
Sponsor
JS InnoPharm, LLC
ID
NCT04418167
Phase
Phase 1 research study
Study Type
Interventional
Participants
About 71 people participating
Last Updated